We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adjuvant Trastuzumab for Breast Cancer Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial.
- Authors
Younis, Tallal; Skedgel, Chris
- Abstract
The article looks at clinical efficacy and "value for money," associated with Adjuvant Trastuzumab for breast cancer, following early stopping of the HERA (Herceptin® Adjuvant) trial. It is mentioned that HERA trial of several thousand cancer patient versus observation after adjuvant chemotherapy was investigated. It is found that there are clinical and economic uncertainties surrounding the magnitude and duration of treatment.
- Subjects
BREAST cancer treatment; MEDICAL care costs; RANDOMIZED controlled trials; DRUG therapy; IMMUNOLOGICAL adjuvants
- Publication
PharmacoEconomics, 2011, Vol 29, Issue 5, p361
- ISSN
1170-7690
- Publication type
Article
- DOI
10.2165/11588350-000000000-00000